NCT01674855View on ClinicalTrials.gov

Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia

PHASE3CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

May 31, 2013

Conditions
Chemotherapy Induced Neutropenia
Interventions
DRUG

PEG-G-CSF

Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle

DRUG

G-CSF

Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle

Trial Locations (1)

152-703

Korea University GURO hospital, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT01674855 - Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia | Biotech Hunter | Biotech Hunter